Soy Linked to Breast Cancer Growth in Women with the Disease
the Cancer Therapy Advisor take:
According to a new study published in the Journal of the National Cancer Institute, soy protein may enhance gene activity that is associated with breast cancer growth in women who already have breast cancer. Jacqueline Bromberg, MD, PhD, from Memorial Sloan Kettering Cancer Center in New York, New York, and her colleagues assigned 140 women with newly diagnosed, early-stage breast cancer to either take a soy protein supplement every day for up to 4 weeks or milk powder.
The researchers found that about 20% of those who took the soy supplement had increased blood concentrations of genistein, a soy phytoestrogen, and some of those women had increased gene activity that promotes breast cancer proliferation and metastasis; however, the study did not show that those women's breast cancers had increased proliferation.
The researchers suggest that women with breast cancer consume food containing soy in moderation and avoid soy-containing supplements to be safe. The benefits and harms from eating soy may depend on how old a woman is. Women in their 60's that consume soy may have more breast cancer death than younger women.
Soy supplement increased gene activity that promotes breast cancer.
Soy protein may increase activity in genes linked to breast cancer growth -- at least in certain women who already have the disease, a new study suggests.
Experts said the findings, reported in the Sept. 4 Journal of the National Cancer Institute, shouldn't scare women off from eating tofu. But to be safe, the researchers suggest women with breast cancer eat soy foods only in moderation and avoid supplements. And for women who don't have breast cancer?
"This study doesn't tell us anything about whether soy raises the risk of developing breast cancer," said researcher Dr. Jacqueline Bromberg, a breast cancer specialist at Memorial Sloan Kettering Cancer Center in New York City.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer